S7E10: Fresh from Munich: Plozasiran and the SHASTA-3 & SHASTA-4 Trial Results

(904) 998-0854

Podcasts

S7E10: Fresh from Munich: Plozasiran and the SHASTA-3 & SHASTA-4 Trial Results

Peter H. Jones, MD, MNLA · Christie M. Ballantyne, MD, FNLA

Posted September 4, 2026

Host

Peter H. Jones, MD, MNLA

Professor Emeritus
Baylor College of Medicine
Houston, TX

Guest

Christie M. Ballantyne, MD, MNLA

Chief, Section of Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Professor of Medicine, Molecular & Human Genetics, and Integrative Physiology, Baylor College of Medicine

Hot off the European Society of Cardiology Congress in Munich, this Lipid Insights episode takes a closer look at a significant announcement in triglyceride science and its implications for clinical practice. Host Peter H. Jones, MD, MNLA sits down with Christie M. Ballantyne, MD, MNLA to discuss the 12-month pivotal trial results from SHASTA-3 and SHASTA-4 — evaluating plozasiran in patients with severe hypertriglyceridemia. If you missed Munich, this is your catch-up.